A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

Medpace said late Wednesday that it had $789 million in new orders in the third quarter, up about 49% from the year-ago ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Leverage RWE strategically to build regulator-ready submissions.

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

On October 2, Novonesis opened the doors of its North American headquarters in Franklinton inviting over 300 high school ...

Safety results showed no increase in immune-mediated adverse events (34.0% vs 38.4%) or treatment-related adverse events ...

Intensity Therapeutics Inc., a clinical-stage biotechnology company based in Shelton, announced this week that its ...